« Highlights of the 5-year results of ContinuationPV study presented at ASH20 showing long-term hematological and deep molecular responses with ropeginterferon including eradication of JAK mutation in selected patients »
Long term use of ropeginterferon alpha in Polycy... - MPN Voice
Long term use of ropeginterferon alpha in Polycythemia Vera
Written by
Manouche
To view profiles and participate in discussions please or .
1 Reply
•
Now if the FDA would just get on the ball, I could switch from Pegasys.
Not what you're looking for?
You may also like...
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment
Discussion;
The results in our study demonstrate that the new dosing regimen of 250-350-500 µg of...
Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera
Summary of Results:
Therapeutic phlebotomies were essentially eliminated and a target hematocrit...
FDA Approves Ropeginterferon Alfa-2b-njft for Polycythemia Vera
The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for use as a treatment in patients...
Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
What were the results?
Over a lifetime, the model showed that patients who received...
Polycythemia vera
Hello. I'm here on behalf of my husband .
He had a heart attack and 2 stents put in at that time....
Related Posts
- Bomedemstat in Patients With Polycythemia Vera
diagnosed with Polycythemia Vera - Ropeginterferon-Treated Patients With Polycythemia Vera Significantly More Likely to Be Phlebotomy Free at 5 Years
New Study: Predicted Survival in Polycythemia Vera Patients- FDA Rejects Ropeginterferon alfa-2b for Polycythemia Vera
